2026/2685(DEA)
Examination of variations to the terms of marketing authorisations for medicinal products for human use
Basic information
2026/2685(DEA)
DEA - Delegated acts procedure
Supplementing 1999/0134(COD)
Subject
4.20.01 Medicine, diseases
4.20.04 Pharmaceutical products and industry
Status
Awaiting committee decision
Key players
-
European Parliament
Committee responsible Rapporteur Appointed SANT
Key events
| Date | Event | Reference | Summary |
|---|---|---|---|
| 20/04/2026 | Non-legislative basic document published | C(2026)02491 | |
| 20/04/2026 | Initial period for examining delegated act 3 month(s) | ||
| 29/04/2026 | Committee referral announced in Parliament |
Technical information
| Procedure reference | 2026/2685(DEA) |
|---|---|
| Procedure type | DEA - Delegated acts procedure |
| Procedure subtype | Examination of delegated act |
| Amendments and repeals | Supplementing 1999/0134(COD) |
| Stage reached in procedure | Awaiting committee decision |
| Committee dossier |
SANT/10/05613
|
Documentation gateway
-
Document type Reference Date Summary Non-legislative basic document C(2026)02491 20/04/2026
Additional information
| Source | Document | Date |
|---|---|---|
| European Commission | EUR-Lex |